

William Louv to Step Down as Chief Executive Officer of CEO Roundtable on Cancer

Louv has served as CEO of the Roundtable since 2022 and as president of Project Data Sphere® since the Roundtable formed the research initiative in March 2018.

CARY, NORTH CAROLINA, UNITED STATES, November 21, 2023 /EINPresswire.com/ -- The [CEO Roundtable on Cancer](#) announced today that William C. Louv, PhD, will step down as the organization's chief executive officer on Dec. 31, 2023. A search is underway to find a successor.

Louv has served as CEO of the Roundtable since 2022 and as president of [Project Data Sphere®](#) since the Roundtable formed the research initiative in March 2018.

Under Louv's leadership, the Roundtable expanded its membership while also launching several new projects, including its Going for Gold initiative with historically black colleges and universities and Hispanic-serving institutions across the United States.



William C. Louv, PhD

"It has been a privilege to serve an organization that has made real strides in reducing the risk of cancer, enabling early diagnoses, and improving access to oncology clinical trials and quality cancer care," said Louv.

"Bill's experience with big data and analytics has made the Roundtable an even more effective tool in the fight against cancer," said David Reese, PhD, chair of the Roundtable's Board of Directors. "We have benefited tremendously from his leadership and insight."

Louv joined the pharmaceutical industry in 1986 as head of biostatistics at Merrell Dow and advanced to vice president of Biostatistics, Epidemiology, and Clinical Data Management at GlaxoWellcome in 1998. He made a significant career change in 1999, when he became vice president of IT for GlaxoSmithKline's R&D organization. He was named chief information officer for GSK in 2007.



Bill's experience with big data and analytics has made the Roundtable an even more effective tool in the fight against cancer."

David Reese, PhD, chair of the Roundtable's Board of Directors

In 2011, Louv was promoted to senior vice president of core business services, which included IT, procurement, accounting, and real estate. He was a member of GSK's Corporate Executive Management team from 2007 until his retirement in May 2016.

Louv has consulted with many organizations on health care analytics and opportunities to leverage big data. He is a non-executive director of River Logic Inc., a leader in prescriptive analytics and integrated business planning.

In his early career, Louv was a member of the technical staff at Bell Laboratories where he developed forecasting algorithms for signaling networks. He later served as an associate professor of biostatistics at the University of Alabama at Birmingham. While at these organizations, he published more than 25 academic papers.

About the CEO Roundtable on Cancer

The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded by creating the CEO Cancer Gold Standard® which calls for organizations to evaluate their health benefits and workplace culture and take extensive, concrete actions in five key areas of health and wellness to address cancer in the workplace. This was followed by Project Data Sphere®, an initiative spanning industry, academia, and government to improve oncology clinical trials. For more information, visit www.ceoroundtableoncancer.org.

Mark Slagle

CEO Roundtable on Cancer

+1 919-360-7343

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/670034630>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.